The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy

Introduction: Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disease. It characterized by persistent pruritus, usually occurring after 30 weeks pregnancy, and elevated levels bile acids transaminases, which decrease over course 2-3 postpartum. [1,2]The occurrence ICP in mother may be associated with significant complications fetus, such as: preterm labor, intrauterine asphyxia, or sudden fetal death. Currently, treatment choice ursodeoxycholic acid (UDCA).[2,6] Recently, it was observed that administration metformin cases not responding to standard therapy improved lipid disorders pregnant women.
 
 The aim study: study present possibility using women a clinical case..
 Material methods: work review literature on management use metabolism disorders, as well brief case report patient intrahepatic pregnancy.
 Description state knowledge: Metformin an oral antidiabetic drug belonging group biguanides. However, latest observations show also has beneficial effect function women. In these patients, enzymes decreased metformin.
 Summary: mechanism action explaining its fully understood.